These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 22681244)

  • 21. Update on treatment regimens: prophylaxis versus on-demand therapy.
    Manco-Johnson MJ
    Semin Hematol; 2003 Jul; 40(3 Suppl 3):3-9. PubMed ID: 14690062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylaxis in real life scenarios.
    Fischer K; Konkle B; Broderick C; Kessler CM
    Haemophilia; 2014 May; 20 Suppl 4():106-13. PubMed ID: 24762285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemophilia and prophylaxis.
    Ljung R
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S23-6. PubMed ID: 23109472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs.
    Tagliaferri A; Franchini M; Coppola A; Rivolta GF; Santoro C; Rossetti G; Feola G; Zanon E; Dragani A; Iannaccaro P; Radossi P; Mannucci PM
    Haemophilia; 2008 Sep; 14(5):945-51. PubMed ID: 18540895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
    Fischer K; Valentino L; Ljung R; Blanchette V
    Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
    Berntorp E
    Haemophilia; 2009 Nov; 15(6):1219-27. PubMed ID: 19659939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An objective method for assessing adherence to prophylaxis in adults with severe haemophilia.
    Ho S; Gue D; McIntosh K; Bucevska M; Yang M; Jackson S
    Haemophilia; 2014 Jan; 20(1):39-43. PubMed ID: 23919911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
    Björkman S; Folkesson A; Berntorp E
    Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia.
    van den Berg HM; Fischer K; Mauser-Bunschoten EP; Beek FJ; Roosendaal G; van der Bom JG; Nieuwenhuis HK
    Br J Haematol; 2001 Mar; 112(3):561-5. PubMed ID: 11260054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.
    Antunes SV; Tangada S; Stasyshyn O; Mamonov V; Phillips J; Guzman-Becerra N; Grigorian A; Ewenstein B; Wong WY
    Haemophilia; 2014 Jan; 20(1):65-72. PubMed ID: 23910578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Models of prophylaxis.
    Berntorp E; Fischer K; Miners A
    Haemophilia; 2012 Jul; 18 Suppl 4():136-40. PubMed ID: 22726097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
    Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
    N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States.
    Witmer C; Presley R; Kulkarni R; Soucie JM; Manno CS; Raffini L
    Br J Haematol; 2011 Jan; 152(2):211-6. PubMed ID: 21114482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The overall effectiveness of prophylaxis in severe haemophilia.
    Panicker J; Warrier I; Thomas R; Lusher JM
    Haemophilia; 2003 May; 9(3):272-8. PubMed ID: 12694517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of haemophilic synovitis: prophylaxis.
    Lee CA
    Haemophilia; 2007 Nov; 13 Suppl 3():20-5. PubMed ID: 17822517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañes M; Paez A
    Haemophilia; 2010 Mar; 16(2):240-6. PubMed ID: 20015218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.